(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.85%.
Cocrystal Pharma's earnings in 2024 is -$17,928,000.On average, 3 Wall Street analysts forecast COCP's earnings for 2024 to be -$19,737,153, with the lowest COCP earnings forecast at -$21,568,435, and the highest COCP earnings forecast at -$16,990,229. On average, 3 Wall Street analysts forecast COCP's earnings for 2025 to be -$22,450,502, with the lowest COCP earnings forecast at -$25,841,427, and the highest COCP earnings forecast at -$16,685,016.
In 2026, COCP is forecast to generate -$26,248,378 in earnings, with the lowest earnings forecast at -$26,248,378 and the highest earnings forecast at -$26,248,378.